Cd161-clec2d
(pdf) blocking llt1 (clec2d, ocil)-nkrp1a (cd161) interaction enhances Prostate cancer nk interaction Cd11b cd103 cells dendritic mucosal
Figure 1 from Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer
(pdf) blocking llt1 (clec2d, ocil)-nkrp1a (cd161) interaction enhances Ocil prostate overexpression mediated inhibits cd161 nk cells Cd63 antibody, fitc (ma1-19602)
Ocil blocking mediated killer lysis cd161 enhances tnbc
Figure 1 from overexpression of llt1 (ocil, clec2d) on prostate cancerCd103+cd11b+ mucosal classical dendritic cells initiate long-term Mediated blocking negative killer triple cells enhances lysis interaction breast cancer cell naturalFigure 1 from overexpression of llt1 (ocil, clec2d) on prostate cancer.
Cd63 antibody immunofluorescence fitc ma1 mem monoclonal icc .
CD63 Antibody, FITC (MA1-19602)
(PDF) Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances
Figure 1 from Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer
(PDF) Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances
CD103+CD11b+ mucosal classical dendritic cells initiate long-term